Global Hemophilia Market (2021 to 2026) - Growth, Trends, COVID-19 Impact and Forecasts - ResearchAndMarkets.com
Retrieved on:
Wednesday, January 19, 2022
Pharmaceutical, Genetics, Health, Other Health, BioMarin Pharmaceutical, Patient, Research, Haemophilia A, Bleeding, Coagulation, NHF, Growth, BMN, DNA, World Federation of Hemophilia, Factor, Genzyme, Association, World government, National Health Federation, Coagulopathy, FDA, Prevalence, Awareness, Vaccine, Pharmaceutical industry, Haemophilia
Replacement therapy, providing the missing coagulation factor, has been the mainstay of treatment both prophylactically and to treat bleeding.
Key Points:
- Replacement therapy, providing the missing coagulation factor, has been the mainstay of treatment both prophylactically and to treat bleeding.
- According to the data published by the World Federation of Hemophilia in 2019, hemophilia is more recorded among males, and approximately 24.6 in 100.000 neonates suffer from hemophilia A.
- According to the World Federation of Hemophilia 2018 report, in 2018, there were about 17,757 people diagnosed with hemophilia in the United States.
- In the United States, agencies, like hemophilia Association of America, generally offers continuous treatment for patients by introducing different co-pay initiatives.